Save your place

Sign in to WhoBought

Please try again later.

Prime Medicine, Inc. (PRME) institutional ownership

Latest close $3.01 Jul 27, 2026
Market cap$543M 52-week range SectorHealthcare
Funds holding · Q1 2026
178
reported PRME position changes
Top owners · Q1 2026
No disclosed owners are available.
Institutional activity · Q1 2026
Activity unavailable N/A
104 buyers · 74 sellers

Prime Medicine, Inc. (PRME) price and institutional activity

Dates

Q1 2026

$0 bought by 104 investors
Adar1 Capital Management, LLCRedmile Group, LLC +102 more
$0 sold by 74 investors
Goldman Sachs Group IncPoint72 Asset Management, L.P. +72 more
Bought Sold Totals per quarter; hover a bar for the names.

Prime Medicine, Inc. (PRME) institutional activity · 178

Investor Type Est. change Change Δ Own Date
Adar1 Capital Management, LLC · New
Change +2.0M Date Q1 2026
Adar1 Capital Management, LLC New· Q1 2026 +2.0M Q1 2026
Redmile Group, LLC · New
Change +1.6M Date Q1 2026
Redmile Group, LLC New· Q1 2026 +1.6M Q1 2026
State Street · Added
Change +1.2M Date Q1 2026
State Street Added· Q1 2026 +1.2M Q1 2026
Balyasny Asset Management L.P. · Added
Change +999K Date Q1 2026
Balyasny Asset Management L.P. Added· Q1 2026 +999K Q1 2026
Ark Investment Management LLC Added· Q1 2026 +878K +16.4% Q1 2026
Goldman Sachs Group Inc · Reduced
Change −785K Date Q1 2026
Goldman Sachs Group Inc Reduced· Q1 2026 −785K Q1 2026
Point72 Asset Management, L.P. · Exited
Change −551K Δ Own −100.0% Date Q1 2026
Point72 Asset Management, L.P. Exited· Q1 2026 −551K −100.0% Q1 2026
Morgan Stanley · Reduced
Change −530K Date Q1 2026
Morgan Stanley Reduced· Q1 2026 −530K Q1 2026
T. Rowe Price Investment Management, Inc. · Reduced
Change −513K Date Q1 2026
T. Rowe Price Investment Management, Inc. Reduced· Q1 2026 −513K Q1 2026
Susquehanna International Group, LLP · Reduced
Change −461K Date Q1 2026
Susquehanna International Group, LLP Reduced· Q1 2026 −461K Q1 2026
UBS Group AG · Added
Change +448K Date Q1 2026
UBS Group AG Added· Q1 2026 +448K Q1 2026
Alessandra Capital Management, LLC · New
Change +426K Date Q1 2026
Alessandra Capital Management, LLC New· Q1 2026 +426K Q1 2026
JPMorgan Chase & Co · Added
Change +408K Date Q1 2026
JPMorgan Chase & Co Added· Q1 2026 +408K Q1 2026
Renaissance Technologies LLC Reduced· Q1 2026 −408K −35.5% Q1 2026
FMR LLC · Reduced
Change −407K Δ Own −18.7% Date Q1 2026
FMR LLC Reduced· Q1 2026 −407K −18.7% Q1 2026
Data through Q1 2026 · filed Jun 4, 2026
15 of 178

Famous investor activity in Prime Medicine, Inc. (PRME)

Prime Medicine, Inc. (PRME) insider trading

Company insiders, action and economics first; trade and filed dates last.
Dates
Insider Title Type Price Qty Value Owned ΔOwn Trade date Filed date
Schenkein David P. · Director Grant (A) 75K
Owned 75K Trade date Jun 5, 2026 Filed date Jun 8, 2026
Schenkein David P. Director Grant (A) 75K 75K Jun 5, 2026 Jun 8, 2026
Marrazzo Jeffrey D. · Director Grant (A) 75K
Owned 75K Trade date Jun 5, 2026 Filed date Jun 8, 2026
Marrazzo Jeffrey D. Director Grant (A) 75K 75K Jun 5, 2026 Jun 8, 2026
Nelsen Robert · Director Grant (A) 75K
Owned 75K Trade date Jun 5, 2026 Filed date Jun 8, 2026
Nelsen Robert Director Grant (A) 75K 75K Jun 5, 2026 Jun 8, 2026
Kelly Michael Aaron · Director Grant (A) 75K
Owned 75K Trade date Jun 5, 2026 Filed date Jun 8, 2026
Kelly Michael Aaron Director Grant (A) 75K 75K Jun 5, 2026 Jun 8, 2026
Foster-Cheek Kaye I. · Director Grant (A) 75K
Owned 75K Trade date Jun 5, 2026 Filed date Jun 8, 2026
Foster-Cheek Kaye I. Director Grant (A) 75K 75K Jun 5, 2026 Jun 8, 2026
Chung Wendy · Director Grant (A) 75K
Owned 75K Trade date Jun 5, 2026 Filed date Jun 8, 2026
Chung Wendy Director Grant (A) 75K 75K Jun 5, 2026 Jun 8, 2026
Cahill Thomas · Director Grant (A) 75K
Owned 75K Trade date Jun 5, 2026 Filed date Jun 8, 2026
Cahill Thomas Director Grant (A) 75K 75K Jun 5, 2026 Jun 8, 2026
Makhni Svetlana Ni · CFO Grant (A) 800K
Owned 800K Trade date Apr 16, 2026 Filed date Apr 17, 2026
Makhni Svetlana Ni CFO Grant (A) 800K 800K Apr 16, 2026 Apr 17, 2026
Reine Allan · Director, Officer Grant (A) 1.3M
Owned 1.3M Trade date Feb 26, 2026 Filed date Feb 27, 2026
Reine Allan Director, Officer Grant (A) 1.3M 1.3M Feb 26, 2026 Feb 27, 2026
Lee Ann L. · Officer Grant (A) 375K
Owned 375K Trade date Feb 23, 2026 Filed date Feb 24, 2026
Lee Ann L. Officer Grant (A) 375K 375K Feb 23, 2026 Feb 24, 2026
Alenson Carman · Officer Grant (A) 140K
Owned 140K Trade date Feb 23, 2026 Filed date Feb 24, 2026
Alenson Carman Officer Grant (A) 140K 140K Feb 23, 2026 Feb 24, 2026
Lee Ann L. · Officer 2 operations -362K
Owned 0 Trade date Aug 1, 2025 Filed date Aug 5, 2025
Lee Ann L. Officer 2 operations -362K 0 Aug 1, 2025 Aug 5, 2025
Lee Ann L. · Officer 2 operations 362K
Owned 181K Trade date Aug 1, 2025 Filed date Aug 5, 2025
Lee Ann L. Officer 2 operations 362K 181K Aug 1, 2025 Aug 5, 2025
Schenkein David P. · Director 2 operations -84K
Owned 0 Trade date Aug 1, 2025 Filed date Aug 5, 2025
Schenkein David P. Director 2 operations -84K 0 Aug 1, 2025 Aug 5, 2025
Schenkein David P. · Director 2 operations 84K
Owned 39K Trade date Aug 1, 2025 Filed date Aug 5, 2025
Schenkein David P. Director 2 operations 84K 39K Aug 1, 2025 Aug 5, 2025
15 of 35
15 of 35 Sign in to continue to older insider transactions.

Prime Medicine, Inc. (PRME) activist and large shareholders

Dates
Owner/Filer identity Shares reported % of shares outstanding Filing date
Arch Venture Fund X, L.P. 12.3M
% of shares outstanding 12.6% Filing date Feb 13, 2023
Arch Venture Fund X, L.P. 12.3M 12.6% Feb 13, 2023
Arch Venture Fund Xii, L.P. 15.5M
% of shares outstanding 11.8% Filing date Nov 22, 2024
Arch Venture Fund Xii, L.P. 15.5M 11.8% Nov 22, 2024
Bristol Myers Squibb Co 11.0M
% of shares outstanding 8.4% Filing date Oct 4, 2024
Bristol Myers Squibb Co 11.0M 8.4% Oct 4, 2024
Gv 2019, L.P. 10.1M
% of shares outstanding 8.2% Filing date Feb 29, 2024
Gv 2019, L.P. 10.1M 8.2% Feb 29, 2024
FMR LLC 7.7M
% of shares outstanding 6.4% Filing date Nov 12, 2024
FMR LLC 7.7M 6.4% Nov 12, 2024
Newpath Partners, L.P. 6.1M
% of shares outstanding 4.7% Filing date Feb 14, 2025
Newpath Partners, L.P. 6.1M 4.7% Feb 14, 2025
6 of 6

Prime Medicine, Inc. (PRME) ownership FAQ

Who owns PRME?

178 reporting institutions disclosed PRME position changes in the Q1 2026 snapshot.

How is institutional activity calculated?

For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.

What are activist and large shareholder filings?

An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.

Where does this data come from?

Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.

Why are ownership reports delayed?

Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.

How are missing table values shown?

A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.